LYEL

13.8001.62%
SR

Stanley R. Riddell

Founder & Scientific Advisor

Prof. Stanley R. Riddell, also known as Stan, MD, is Founder & Scientific Advisor of Lyell Immunopharma, Inc. since August 2022. He serves as Member of Scientific Advisory Board at Typewriter Therapeutics, Inc. from September 2026. Prof. Riddell is Member of Scientific Advisory Council of Cancer Research Institute, Inc. He serves as Member of Scientific Advisory Board and Member of Cancer Center Advisory Board at St. Jude Children's Research Hospital, Inc. Prof. Riddell served as Head of Research and Development of Lyell Immunopharma, Inc. until 2020. Prof. Riddell is Scientific Co-Founder of Juno Therapeutics Inc. Prof. Riddell is a Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor of Oncology at the University of Washington School of Medicine. Prof. Riddell is a leader in developing therapies that harness the immune system to fight cancer and infectious diseases. His research led to patented technologies that rapidly expand the number of disease fighting T cells used in adoptive immunotherapy. He also isolated a rare subset of disease-fighting T cells that survive in patients for an extraordinary amount of time. He joined FHCRC Faculty in 1991 after training in medical oncology and immunology. Prof. Riddell was elected to the Association of American Physicians, an organization honoring those who have achieved excellence in biomedical science. He served as an Associate Professor of University of Washington School of Medicine, since 2000. Prof. Riddell serves as a Member of Scientific Advisory Board of Cellerant Therapeutics Inc. He serves as Member of Scientific Advisory Team of Kuur Therapeutics Limited (formerly known as Cell Medica Limited). He is a Member of the American Association for the Advancement of Science, the American Society of Gene Therapy and the American Society of Hematology. He is the recipient of ASCO Young Investigator Award and the Cancer Research Institute Partridge Foundation Investigator Award. In 2010, Prof. Riddell received the International Society for Biological Therapy of Cancer’s first Team Science Award for major contributions to research and the clinical translation of cancer immunotherapy. Prof. Riddell earned his M.D. at University of Manitoba and is a Board Certified Medical Oncologist.

Positions